Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...
A previous needle electromyogram had confirmed the presence of myotonia, but a muscle biopsy had revealed no evidence of dystrophy. Investigations Neurological examination, electrophysiological ...
Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder ...
How does exercise benefit health? Molecules called exerkines partly regulate its effects and provide therapeutic targets to ...
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler ...
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...
We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...